On October 7, METIS TECHBIO-P fell 5.08% in regular trading, reflecting broad weakness across Hong Kong-listed biotechnology names. The stock traded at HK$16.51 with turnover of HK$5.31 million in early dealing.
Within the biotechnology sector, overall sentiment was subdued, with Innovent Bio down 2.31%, Akeso down 2.17%, CanSinoBio down 7.00%, BeOne Medicines down 1.99%, and HBM Holdings-B down 6.67%.
METIS TECHBIO-P, formerly known as Metis Technology (Beijing) Co., Ltd., is a China-based company focused on artificial intelligence-driven nanomaterial innovation. Its core platform, NanoForge, underpins the company's AI-powered nanomedicine development system, encompassing lipid libraries, AI foundation models, the METiS AI agent, quantum chemistry and molecular dynamics simulations, and AI-driven screening. The company has developed three specialized solution platforms—AiTEM, AiLNP, and AiRNA—to simulate, predict, and elucidate nanoscale interactions for the rational design, optimization, and validation of advanced nanomaterials and their therapeutic payloads.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)